Instruction for Use

【Product Name】

Carbohydrate Antigen 19-9 (eCLIA)

【Order Information】

REF NO.	Package Size
0320500801	50 T
0320500802	2×50 T
0320500803	100 T
0320500804	2×100 T

【Intended Purpose】

Carbohydrate Antigen 19-9 (eCLIA) is an immunoassay reagent for in vitro quantitative determination of Carbohydrate Antigen 19-9 (CA19-9) in human serum or plasma by fully automated immunassay analyzer monitor the therapeutic effect of pancreatic and other digestive tract malignant tumors.

【Summary】

Screening: Serum CA19-9 is generally not used for screening pancreatic cancer;

Auxiliary diagnosis: it is used for the auxiliary diagnosis of malignant tumors such as pancreas and bile duct, but the specificity is not strong enough. The measured value of CA19-9 has no relationship with the size of pancreatic cancer, but when it is up to 10000 U/mL, there is almost peripheral metastasis[1]. Serum CA19-9 was also certain positive in gastric cancer, colon cancer and liver cancer. The serum levels of CA19-9 and cholangitis are different from those of benign liver cirrhosis and cholangitis[2-4]. 3% to 7% of the patients have Lewis antigen negative blood group structure and do not express CA19-9. Therefore, CA19-9 test results of these patients are often negative[5].

Prognosis evaluation: Serum CA19-9 combined with clinical data can be used as a comprehensive prognostic indicator for pancreatic cancer.

Efficacy and recurrence monitoring: Serum CA19-9, together with imaging examination, can be used to monitor the therapeutic effect of radiotherapy and chemotherapy for pancreatic cancer. The continuous increase of CA19-9 concentration indicates disease progression[6-7]. Serum CA19-9, together with imaging examination, can be used for follow-up and recurrence monitoring of pancreatic cancer after surgical resection. The patients were followed up after the operation every 3 months i the first year, every 6 months in the second to third years, and once a year after three years.

For professionals use only.

【Principle】

Sandwich principle. Total duration of assay: 9 minutes.

10 µL of the sample, biotin labeled CA19-9 antibody and the ruthenium (Ru) complex-labeled CA19-9 antibody form an antigen-antibody sandwich complex, which is bound to streptavidin coated magnetic particles, and then transferred to the measuring cell where the magnetic particles are captured onto the surface of the electrode, while the unbound substances are washed away. Chemiluminescence is generated after the electrode is electrified, and the generated optical signal is measured by a photomultiplier, processed by an instrument, and the concentration of CA19-9 in the sample is calculated based on the calibration curve.

【Composition】

The reagent pack consists of MB, RA, RB, calibrators and control materials (optional), and different components and reagents of lot numbers should not be used interchangeably.

Components	Ingredients	Content (2×50 T)	Content (50 T)	Content (100 T)	Content (2×100 T)
Magnetic Beads (MB)	Streptavidin coated magnetic particles, 0.45 mg/mL; 0.1 M phosphate-buffered saline (PBS); ProClin™300	2×1.8 mL	1×1.8 mL	1×3.5 mL	2×3.5 mL
Reagent B (RB)	Biotinylated CA19-9 antibody, 3.0 mg/L; 50 mM HEPES; ProClin™300	2×3.8 mL	1×3.8 mL	1×7.5 mL	2×7.5 mL
Reagent A (RA)	Ru complex-labeled CA19-9 antibody, 1.5 mg/L; 50 mM HEPES; ProClin™300	2×3.8 mL	1×3.8 mL	1×7.5 mL	2×7.5 mL
CA19-9 Calibrators	CA19-9 antigen, 100 mM PBS pH7.4, ProClin™300	High: 1×1.0 mL Low: 1×1.0 mL			
CA19-9 Control Materials (Optional)	CA19-9 antigen, 100 mM PBS pH7.4, ProClin™300	High: 1×1.0 mL Low: 1×1.0 mL			

Traceability:This method can be traceable to the Roche ELecsys CA19-9.

See the control material value sheet for the target values and ranges of control materials.

Supporting instruments and materials required but not provided in this pack (provided by Lifotronic).

【Instruments and Materials Required but Not Provided】

What for Automated ECL Immunoassay Analyzer eCL8000, eCL8000i, eCL8000p, eCL8000x:

- REF 679005, Auffer, 480 mL, or REF 679004, Auffer, 6×480 mL
- REF 679007, Buffer, 480 mL, or REF 679006, Buffer, 6×480 mL
- REF 679009, Concentrated Washing Buffer, 1 L, or REF 679008, Concentrated Washing Buffer, 6×1 L
- REF 679011, Assay Cup, 300 T, or REF 679012, Assay Cup, 3000 T

Additional materials for Automated ECL Immunoassay Analyzer eCL8600, eCL8600i, eCL8600p, eCL8800, eCL8800i, eCL8800p:

- REF 0320501804, Auffer, 2×1 L, or REF 0320501805, Auffer, 4×1 L
- REF 0320507502, PreClean, 2×800 mL, or REF 0320507503, PreClean, 4×800 mL
- REF 0320510001, Assay Cup/Assay Tip, 6×6×105, or REF 032120111, Assay Cup/Assay Tip, 12×2×105

Additional materials for Automated ECL Immunoassay Analyzer eCL9000, eCL9600, eCL9900, eCL9900i:

- REF 0320501801, Auffer, 2×2 L, or REF 0320501806, Auffer, 4×2 L
- REF 0320501901, Buffer, 2×2 L, or REF 0320501906, Buffer, 4×2 L
- REF 0320507501, PreClean, 2×2 L, or REF 0320507504, PreClean, 4×2 L
- REF 0320510001, Assay Cup/Assay Tip, 6×6×105, or REF 0320510002, Assay Cup/Assay Tip, 1×6×105

【Applicable Instrument】

Automated ECL Immunoassay Analyzers: eCL8000, eCL8000i, eCL8000p, eCL8000x, eCL8600, eCL8600i, eCL8600p, eCL8800, eCL8800i, eCL8800p, eCL9000, eCL9600, eCL9900, eCL9900i.

【Storage and Shelf life】

Store at 2ºC~8ºC.

Do not freeze.

Store the reagent kit upright in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability of the reagents	
Unopened store at 2ºC~8ºC	18 months
Store at 2ºC~8ºC after opening	8 weeks
on the analyzers at 2ºC~15ºC	8 weeks

The Calibrators and Control Materials are stable up to the stated expiration date.

Stability of the Calibrators and Control Materials	
Unopened store at 2ºC~8ºC	18 months
Store at 2ºC~8ºC after opening	8 weeks

【Specimen collection, handling and storage】

It is recommended to use human serum samples or plasma samples collected with EDTA-K2, EDTA-K3, heparin lithium blood collection tubes.

Blood samples should be collected in accordance with the standard operation of venipuncture. After the sample is completely coagulated, centrifugation should be performed to remove residual cellular substances. The sample should be free of air bubbles during testing. Lipid layer floating on the upper of the sample should be removed. It is not recommended to use hemolyzed samples.

Samples can be stored for 3 days at 18~28ºC, 8 days at 2~8ºC, and 3 months at -15ºC or below. Samples should avoid repeated freeze-thaw cycles and samples can only be freeze-thawed three times.

【Testing Procedure】

Testing procedure and precautions

Before testing, the system operation manual of the measuring instrument should be carefully read, so as to obtain relevant information such as system operating procedures, sample management, safety precautions and maintenance, and materials required for testing should be prepared. CA19-9 testing procedures should be called and set up in accordance with the system operating procedures.

Before using the reagent, put it into the analyzer 30 minutes in advance to automatically stir the magnetic bead particles and keep them in suspension.

Recommended environment temperature for testing: 10~30ºC; relative humidity: ≤ 80%.

Calibration

Calibration should be performed using lot-matching reagent and calibrators.

Before calibration, the reagent and main curve information should be imported into the analyzer via radio frequency identification reagent card (refer to instrument user manual). The analyzer adjusts the main curve to produce working curve according to the calibrator results, and identifies validity of the working curve automatically.

Recalibration is recommended when:

(1) The reagents of different lot are used;

(2) The same lot of reagents were used on the analyzer beyond 28 days;

(3) Quality control findings outside the defined limits.

(4) The Buffer of different lots are used.

Quality Control procedure

For quality control, use CA19-9 control materials.

In addition, other suitable control material can be used.

Control materials for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

Please make sure that the correct values are used.

Calculation

The system software can automatically calculate the analyte concentration, with the result in U/mL.

Specimen dilution

CA19-9 concentration in the sample higher than the upper limit of detection can be diluted with sample diluent.

The recommended dilution ratio is 1:10 (automatic dilution by instrument or manual dilution). If manual dilution, the result should be multiplied by the dilution ratio. If instrument automatic dilution, the instrument will automatically calculate the result.

【Reference intervial】

By analyzing the serum samples of healthy people from hospitals in Guangdong, it was calculated that the upper limit of the reference range of 95% is 27.4 U/mL.

Due to the differences in geography, race, gender and age, it is recommended that each laboratory determine the applicability of reference range through tests, and establish the reference range of this laboratory if necessary.

【Limitations】

(1) The test results are only for clinical reference and cannot be used alone as the basis for diagnosis or exclusion of cases.

(2) The detection range of the kit is 0.25~1000 U/mL. If the CA19-9 concentration in the sample is lower than the lower limit of detection, the result is reported as < 0.25 U/mL; if the Ca19-9 concentration in the sample is higher than the upper limit of detection, the result is reported as > 1000 U/mL (10× diluted sample is reported as > 10000 U/mL).

(3) When jaundice (bilirubin) is ≤ 66 mg/dL, hemolysis (hemoglobin) is ≤ 500 mg/dL, lipemia (triglyceride) is ≤ 1500 mg/dL, biotin is ≤ 20 ng/mL, and HAMA is ≤ 100 ng/mL in the sample, the interference deviation of the measured results is within ±15%. When the concentration of rheumatoid factor in the sample is ≤ 1500 IU/mL, the relative recovery rate of the test results is between 85% and 115%.

(4) When the sample contains adriamycin (7 μg/mL), methotrexate (8.5 μg/mL), cyclophosphamide (210 μg/mL), 5-fluorouracil (220 μg/mL), cisplatin (57 μg/mL), gemcitabine (382 μg/mL) Leucocorin (115 μg/mL) and dexamethasone (10 μg/mL), the interference deviation of the measured results is within ±15%.

(5) Samples of other tumor markers containing 1000 ng/mL AFP, 1000 U/mL CA125, 100 U/mL CA15-3, 1000 ng/mL CEA, 100 ng/mL PSA and 1000 ng/mL Ferr are tested, and the CA19-9 measured results are not greater than 10 U/mL.

(6) When the CA19-9 concentration under 350000 U/mL, the test results are not be affected by the high-dose hook effect.

【Analytical Performance charateristics】

Lower limit of measurement

Limit of Blank n = 0.25 U/mL.
Limit of detection = 0.6 U/mL.

Accuracy

The accuracy control subject to standardized traceability is tested, and the relative deviation of its test results is within ± 10%.

Linearity

Within the range of 0.6 U/mL~1000 U/mL, the correlation coefficient (r) of the kit should not be less than 0.9900.

Repeatability

The coefficient of variation (CV) ≤ 5.0%.

Between-run precision

The coefficient of variation (CV)≤ 10.0%.

Homogeneity of calibrators and control materials

In-bottle homogeneity: coefficient of variation (CV) ≤ 5%.
Between-bottle homogeneity: coefficient of variation (CV) ≤ 10%.

Accuracy of calibrators

The supporting calibrators of the kit are tested, the relative deviation of test results is within ±10%.

Measured values of quality control

The measured results of supporting assigned quality control of the kit should be within the quality control range.

Method comparison

A comparison of the Lifotronic CA19-9 assay (y) with the Roche Elecsys CA19-9 Method (x) using clinical samples gave the following correlations:

Number of samples measured: 104

Linear regression:

y=0.963x-0.243

r=0.992

The sample concentrations were between approx 2.06 and 980.9 U/mL.

【Precautions and Warnings】

The kit is only used for in vitro diagnostics.
Exercise the normal precautions required for handling all laboratory reagents.
All reagents and samples including specimen, reagents, calibrators and control materials should avoid foaming before and during test.
Disposal of all waste material should be in accordance with local guidelines.
Safety data sheet available for professional user on request.
This product contains animal-sourced materials and may have potential biological risk. All samples and test wastes should be treated as the source of infection, and all wastes must be disposed according to local regulations.
Any serious incident that would be occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

The preservative ProClin 300 which contains Mixture of 5-Chloro-2-methyl-4-isothiazolin-3-one and 2-Methyl-2H-isothiazol-3-one (3:1): May cause an allergic skin reaction. thus, proper personal protection should be adopt while handling the reagent: avoid breathing dust/fume/gas/mist/vapours/ spray, wear protective gloves and contaminated work clothing should not be allowed out of the workplace. If skin irritation or rash occurs: get medical advice/attention, take off contaminated clothing and wash it before reuse, and dispose of contents/container to an approved waste disposal plant.

【Symbols Explanation】

Symbol	Title of Symbol	Symbol	Title of Symbol
	Manufacturer		Consult instructions for use
	Use-by date	IVD	In vitro diagnostic medical device
LOT	Batch code	Σ	Sufficient for <n> tests
SN	Serial number		Biological risks
	Temperature limit		This way up
EC REP	Authorized representative in the European Community	CE	Indicates this device is in compliance with Europe Directive.
REF	Catalogue number	P/N	Material code
	Warning		Date of manufacture
UDI	Unique device identifier		

【Bibliography】

1. Farini R, Fabris C, Bonvicini P, et al. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis. Eur J Cancer Clin Oncol 1985;21:429-432.

2. Steinberg W K, Gelfand R, Anderson K K, et. al. Comparison of the Sensitivity and Specificity of the CA19-9 and Carcinoembryonic Antigen Assays in Detecting Cancer of the Pancreas. Gastroenterology, 1985, 90: 343-349.

3. Ritts R E Jr, Del Villano B C, Go VLW, et al. Initial Clinical Evaluation of an Immunoradiometric Assay for CA 19-9 Using the NCI Serum Bank. Int J. Cancer, 1984, 33: 339-345.

4. Jalanko H, Kuusela P, Roberts P, et al. Comparison of a New Tumor Marker, CA 19-9, with Alpha-Fetoprotein and Carcinoembryonic Antigen in Patients with Upper Gastrointestinal Diseases. J Clin Pathol, 1984, 37: 218-222.

5. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979;5:957-972.

6. Frebourg T, Bercoff E, Manchon N, et al. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer. 1988;62(11):2287-2290.

7. Glenn J, Steinberg W M, Kurtzman SH, et al. Evaluation of the Utility of a Radioimmunoassay for Serum CA 19-9 Levels in Patients Before and After Treatment of Carcinoma of the Pancreas. J Clin Oncol, 1988, 6 (3): 462-468.

【Manufacturer】

Shenzhen Lifotronic Technology Co., Ltd.
Lifotronic Tower, No. 8, Qiuzhi East Road, Guancheng Community, Guanhu Street, Longhua, 518110 Shenzhen, PEOPLE'S REPUBLIC OF CHINA
E-mail: inter-service@lifotronic.com

【European Representative】

Shanghai International Holding Corp. GmbH (Europe)
Eiffestrasse 80, 20537 Hamburg, Germany
Tel. +49-40-2513175 Fax. +49-40-255726

【Version and Revision】

Version: 2.0
Issue Date: 2025-03-04